Plus Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Plus Therapeutics, Inc. (Nasdaq: PSTV) is a clinical-stage pharmaceutical company focused on the development and commercialization of precision diagnostics and targeted radiotherapeutics for rare, difficult-to-treat cancers of the central nervous system (CNS). The company's lead therapeutic candidate is REYOBIQ™ (rhenium Re-186 obisbemeda), an investigational liposomal radiopharmaceutical being evaluated in clinical trials for recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancer (PBC). Additionally, the company commercializes CNSideu0000, a proprietary cerebrospinal fluid (CSF) molecular diagnostic assay platform designed to identify and quantify tumor cells that have metastasized to the central nervous system.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding nationwide access and commercial adoption of the CNSide cerebrospinal fluid (CSF) assay platform. This includes expanding state licensing, securing national coverage agreements with major payers, and enrolling with Medicare.
Expected impact: Aims to capture a share of the $6 billion+ U.S. addressable market, generating meaningful non-dilutive revenue to fund therapeutic pipeline development.
Advancing the lead radiotherapeutic candidate REYOBIQ (rhenium Re186 obisbemeda) through Phase 2 clinical trials (ReSPECT-LM and ReSPECT-GBM) and preparing for registrational studies.
Expected impact: Establishes a clear regulatory pathway toward FDA approval for difficult-to-treat central nervous system cancers.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
To deploy an AI-native execution platform designed to integrate, organize, and analyze longitudinal therapeutic, diagnostic, and bioinformatic datasets across Plus' CNS oncology programs, improving clinical and laboratory operating efficiency.
Terms: No financial terms were disclosed.
Secures the late-stage development supply chain through cGMP manufacturing of Rhenium-186 for the REYOBIQ therapeutic platform.
Terms: Expanded agreement terms; specific financial details not disclosed.